1. Scrip
  2. >>Business

Will Intercept’s New NASH Analysis Pass FDA’s Muster?

Consensus Method Shows Consistent Efficacy

 
• By Alaric DeArment

The new analysis of REGENERATE, based on an FDA-requested methodology, shows continued efficacy for OCA, but analysts were circumspect about whether the benefit/risk profile would sway the agency.

Intercept announced a new analysis of the pivotal Phase III REGENERATE study • Source: Shutterstock

Intercept Pharmaceuticals, Inc. is hoping that a new analysis of the Phase III REGENERATE study of obeticholic acid (OCA) in non-alcoholic steatohepatitis (NASH) will pass muster with the US Food and Drug Administration when it resubmits its application, but analysts are uncertain that the data change the benefit/risk profile enough to warrant approval instead of another complete response letter (CRL).

Intercept announced on 7 July results of a new analysis of REGENERATE, based on a consensus panel method of reading...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business